GlassScriptPhysician profile
Adnan Taj-Eldin
NPI 1770501678
$11,719.34
in general payments reported to CMS, 2019-2025
39 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,272 · 2020: $1,793 · 2021: $3,149 · 2022: $1,542 · 2023: $1,813 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,964.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,587.45 | 2019-2023 | Repatha, Prolia, Evenity |
| Glaxosmithkline, LLC. | $1,508.49 | 2019-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $1,447.88 | 2019-2023 | Breztri, Farxiga |
| Abbvie INC. | $934.43 | 2019-2023 | Qulipta, Vraylar, Synthroid |
| Novo Nordisk INC | $760.53 | 2019-2022 | |
| Lilly USA, LLC | $476.83 | 2019-2023 | Jardiance, Emgality |
| Pfizer INC. | $419.77 | 2019-2023 | |
| Esperion Therapeutics, INC. | $410.60 | 2020-2021 | |
| Amarin Pharma, INC. | $387.75 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $372.64 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $331.36 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $295.75 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $254.59 | 2021 | |
| Janssen Pharmaceuticals, INC | $192.46 | 2019 | |
| Astellas Pharma US INC | $182.66 | 2021-2023 | Veozah |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adnan Taj-Eldin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.